Sign up Australia
Proactive Investors - Run By Investors For Investors

Phylogica aligns with Cubist Pharmaceuticals to develop new antibiotics

Phylogica aligns with Cubist Pharmaceuticals to develop new antibiotics

Phylogica (ASX: PYC) has formed a collaboration with Cubist Pharmaceuticals (NASDAQ: CBST), a US$3.57 billion market cap, to evaluate several of its antimicrobial Phylomers in models of multi-drug resistant bacterial infections.   

The company hopes that its antimicrobial Phylomers will support Cubist’s ongoing work to discover and develop new antibiotics to address the growing global health threat of antibiotic resistance.

In its own assays, these antimicrobials have shown activity against multi-resistant isolates of Gramnegative, which are a major cause of deaths from hospital acquired infections of burn wounds.

The company’s proprietary Phylomer peptide libraries and screening methodologies are used to identify unique peptide drug candidates for its pharmaceutical and biotechnology partners.

These peptides are sourced from evolutionary diverse microbes and they represent a new class of biological therapeutics.

They display structural stability, specificity and affinity that give them the potential to address disease targets that are intractable to small molecules and other protein biologics including antibodies.

Phylogica had recently patented an improvement to its Phylomer peptide platform that will allow more efficient screening of its library of billions of naturally occurring peptides and identify those with the highest potential to target disease proteins inside the cells.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.



Register here to be notified of future PYC Company articles
View full PYC profile

PHYLOGICA LIMITED Timeline

Newswire
October 06 2015
Newswire
November 25 2014
Newswire
November 07 2013

Related Articles

Blood test
September 28 2016
The group has ambitions to strengthen its transatlantic focus through organic and strategic growth
shutterstock_216375733.jpg
January 25 2017
At the moment, the healthcare firm M Pharma is a work in progress
cancer cells
January 25 2017
The US-based, London-listed healthcare group topped expectations with its latest results and analysts are tipping it for more success this year

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.